If your patient is 12+ years and has moderate-to-severe asthma characterized by an eosinophilic phenotype, DUPIXENT is available in 200 mg^s and 300 mg^t doses. The 200 mg treatment, given every 2 weeks, has an initial loading dose of 400 mg (2 x 200 mg pre-filled pens or syringes), and the 300 mg treatment, given every 2 weeks, has an initial loading dose of 600 mg (2 x 300 mg pre-filled pens or syringes).¹

If your patient is 12+ years and has OCS-dependent asthma or comorbid moderate-to-severe atopic dermatitis or is an adult with comorbid chronic rhinosinusitis with nasal polyps, the recommended dose is an initial loading dose of 600 mg (2 x 300 mg pre-filled pens or syringes) followed by every-2-week dosing of a 300 mg pre-filled pen or syringe.¹

If your patient is aged 6-11 years with uncontrolled moderate-to-severe asthma for which DUPIXENT is indicated, the dosing is weight based. For children weighing 15 kg^u to less than 30 kg, the recommended dose is 300 mg given every 4 weeks via a pre-filled pen or syringe. For children weighing 30 kg^v or more, the recommended dose is 200 mg given every 2 weeks via a pre-filled pen or syringe. For children aged 6-11 years with asthma and comorbid moderate-to-severe atopic dermatitis, follow the recommended dosage for atopic dermatitis, which includes an initial loading dose.¹